KEYNOTE-042: Should Pembrolizumab Replace Chemo for Broader Population with Adv. NSCLC?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

KEYNOTE-042: Should Pembrolizumab Replace Chemo for Broader Population with Adv. NSCLC?

By Beacon Medical Interchange FEATURING Jack West

1,926 views

October 29, 2018

Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting ...
read more ↘ key findings from the presentation in the Plenary Session at ASCO 2018, clinical implications, & whether it should change practice.
↖ read less

2 Comments